Haleon PLC ( (GB:HLN) ) just unveiled an announcement.
Haleon PLC announced the acquisition of partnership shares and the award of matching shares to key managerial personnel under the company’s Share Reward Plan. This move, disclosed in compliance with the UK Market Abuse Regulation, involves transactions by Adrian Morris, General Counsel, and Tamara Rogers, Chief Marketing Officer. The transactions, conducted on the London Stock Exchange, reflect Haleon’s commitment to aligning managerial interests with company performance, potentially enhancing stakeholder confidence and reinforcing its market position.
More about Haleon PLC
Haleon PLC is a global leader in the consumer health industry, focusing on delivering better everyday health with humanity. The company offers a diverse product portfolio across five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). Haleon’s well-known brands, including Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, are recognized for their trusted science, innovation, and deep human understanding.
YTD Price Performance: 5.30%
Average Trading Volume: 25,210,631
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £35.98B
Learn more about HLN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com